Who Paid My Doc
Sameer Desai
Hematology & Oncology Somerset, NJ Medical Doctor
NPI 1487776373 CMS profile 340104
75 Veronica Ave, Suite 201, Somerset, NJ 08873
General payments
$26,750
Research payments
$0
Ownership & investment interest
$30,000
Research they led as principal investigator
$37,628
Through program year 2025, Sameer Desai of Somerset, NJ is reported in the CMS Open Payments database as having received $26,750 across 185 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $37,628 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $30,000 across 6 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 84th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
13 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $3,351 | 46 | |
| 2024 | General | $5,371 | 45 | |
| 2023 | General | $9,435 | 41 | |
| 2022 | General | $2,960 | 15 | |
| 2021 | General | $2,817 | 10 | |
| 2020 | General | $495 | 8 | |
| 2019 | General | $2,320 | 20 | |
| 2024 | Ownership | $5,000 | 1 | |
| 2023 | Ownership | $5,000 | 1 | |
| 2022 | Ownership | $5,000 | 1 | |
| 2021 | Ownership | $5,000 | 1 | |
| 2020 | Ownership | $5,000 | 1 | |
| 2019 | Ownership | $5,000 | 1 |
Beside peers
- Sameer Desai
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Sameer Desai were reported at $3,351. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Sameer Desai | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,320 | $529 | $121–$2,516 | $163 |
| 2020 | $495 | $339 | $82–$2,213 | $114 |
| 2021 | $2,817 | $263 | $49–$1,965 | $132 |
| 2022 | $2,960 | $416 | $103–$2,395 | $149 |
| 2023 | $9,435 | $542 | $125–$2,646 | $160 |
| 2024 | $5,371 | $692 | $141–$3,008 | $164 |
| 2025 | $3,351 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 45 drugsPart D claims
1,350
Drug cost
$4,183,449
Branded share of claims
52.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Revlimid Lenalidomide | Brand | 38 | $709,833 | |
| Neulasta Pegfilgrastim | Brand | 61 | $517,940 | |
| Jakafi Ruxolitinib Phosphate | Brand | 25 | $433,083 | |
| Pomalyst Pomalidomide | Brand | 13 | $290,728 | |
| Aranesp Darbepoetin Alfa In Polysorbat | Brand | 91 | $224,510 | |
| Nerlynx Neratinib Maleate | Brand | 11 | $221,850 | |
| Brukinsa Zanubrutinib | Brand | 15 | $208,954 | |
| Xtandi Enzalutamide | Brand | 14 | $194,484 | |
| Lenalidomide | Generic | 12 | $177,534 | |
| Venclexta Venetoclax | Brand | 13 | $140,681 |
The 10 drugs with the highest cost, of 45 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 140 billing codesPaid by Medicare
$2,027,032
Medicare patients
816
Services billed
143,511
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 51% | |
| Diabetes | 47% | |
| Ischemic heart disease | 43% | |
| Chronic kidney disease | 40% | |
| Cancer | 38% | |
| Heart failure | 25% | |
| COPD | 24% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg J1569 | Office | 14 | 2,780 | $97,962 |
| Injection, eflapegrastim-xnst, 0.1 mg J1449 | Office | 16 | 4,620 | $89,250 |
| Injection, denosumab, 1 mg J0897 | Office | 23 | 2,820 | $57,792 |
| Injection, ferric carboxymaltose, 1 mg J1439 | Office | 59 | 60,750 | $52,105 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg J1454 | Office | 20 | 49 | $26,684 |
| Vaccine for influenza for injection into muscle 90653 | Office | 36 | 36 | $2,946 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) J7040 | Office | 22 | 90 | $93 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 | Office | 21 | 76 | $72 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 27 | 710 | $64 |
| Injection, diphenhydramine hcl, up to 50 mg J1200 | Office | 36 | 82 | $52 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 46 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| BRUKINSA |
|
$1,925 | 15 | — |
| LIBTAYO |
|
$40 | — | — |
| KRAZATI |
|
$39 | — | — |
| KEYTRUDA |
|
$38 | — | — |
| FOTIVDA |
|
$29 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 46 with PatronRecords
185 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in New Jersey
Robert Spiegel
Hematology & Oncology · Westfield, NJ
Amit Patel
Hematology & Oncology · Jersey City, NJ
Joshua Strauss
Hematology & Oncology · Springfield, NJ
Charles Farber
Hematology & Oncology · Morristown, NJ
Michael Scola
Hematology & Oncology · Morristown, NJ
Eshan Patel
Hematology & Oncology · Somerville, NJ
Related records
Hematology & Oncology in New Jersey
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in New Jersey
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.